InterMune to pay flat-rate EU Esbriet royalty to settle Shionogi dispute
This article was originally published in Scrip
Executive Summary
Shionogi took legal action in the US against InterMune in July last year, claiming that the US firm had failed to pay due royalties on its sales of the idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) in the EU.